Your browser doesn't support javascript.
loading
Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps.
Marcus, Pamela M; Pashayan, Nora; Church, Timothy R; Doria-Rose, V Paul; Gould, Michael K; Hubbard, Rebecca A; Marrone, Michael; Miglioretti, Diana L; Pharoah, Paul D; Pinsky, Paul F; Rendle, Katherine A; Robbins, Hilary A; Roberts, Megan C; Rolland, Betsy; Schiffman, Mark; Tiro, Jasmin A; Zauber, Ann G; Winn, Deborah M; Khoury, Muin J.
Afiliação
  • Marcus PM; Division of Cancer Control and Population Studies, National Cancer Institute, Bethesda, Maryland. marcusp@mail.nih.gov.
  • Pashayan N; Department of Applied Health Research, University College London, London, England, United Kingdom.
  • Church TR; Division of Environmental Health Sciences, University of Minnesota School of Public Health, Minneapolis, Minnesota.
  • Doria-Rose VP; Division of Cancer Control and Population Studies, National Cancer Institute, Bethesda, Maryland.
  • Gould MK; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
  • Hubbard RA; Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Marrone M; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Miglioretti DL; Department of Public Health Sciences, University of California, Davis, Sacramento, California.
  • Pharoah PD; Department of Public Health and Primary Care and Department of Oncology, University of Cambridge, Cambridge, England, United Kingdom.
  • Pinsky PF; Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.
  • Rendle KA; Division of Cancer Control and Population Studies, National Cancer Institute, Bethesda, Maryland.
  • Robbins HA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Roberts MC; Division of Cancer Control and Population Studies, National Cancer Institute, Bethesda, Maryland.
  • Rolland B; Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
  • Schiffman M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • Tiro JA; Department of Clinical Science, UT Southwestern Medical Center, Dallas, Texas.
  • Zauber AG; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Winn DM; Division of Cancer Control and Population Studies, National Cancer Institute, Bethesda, Maryland.
  • Khoury MJ; Division of Cancer Control and Population Studies, National Cancer Institute, Bethesda, Maryland.
Cancer Epidemiol Biomarkers Prev ; 25(11): 1449-1455, 2016 11.
Article em En | MEDLINE | ID: mdl-27507769
Precision medicine, an emerging approach for disease treatment that takes into account individual variability in genes, environment, and lifestyle, is under consideration for preventive interventions, including cancer screening. On September 29, 2015, the National Cancer Institute sponsored a symposium entitled "Precision Cancer Screening in the General Population: Evidence, Epidemiology, and Next Steps". The goal was two-fold: to share current information on the evidence, practices, and challenges surrounding precision screening for breast, cervical, colorectal, lung, and prostate cancers, and to allow for in-depth discussion among experts in relevant fields regarding how epidemiology and other population sciences can be used to generate evidence to inform precision screening strategies. Attendees concluded that the strength of evidence for efficacy and effectiveness of precision strategies varies by cancer site, that no one research strategy or methodology would be able or appropriate to address the many knowledge gaps in precision screening, and that issues surrounding implementation must be researched as well. Additional discussion needs to occur to identify the high priority research areas in precision cancer screening for pertinent organs and to gather the necessary evidence to determine whether further implementation of precision cancer screening strategies in the general population would be feasible and beneficial. Cancer Epidemiol Biomarkers Prev; 25(11); 1449-55. ©2016 AACR.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Detecção Precoce de Câncer / Medicina de Precisão Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Detecção Precoce de Câncer / Medicina de Precisão Idioma: En Ano de publicação: 2016 Tipo de documento: Article